Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prexige Still Postponed: Novartis To Resubmit COX-2 Inhibitor In U.S. In 2007

Executive Summary

Novartis plans to resubmit Prexige (lumiracoxib) in the U.S. in the first half of 2007; approval of the oral COX-2 inhibitor in the European Union and Canada for treatment of osteoarthritis symptoms was announced Nov. 7
Advertisement

Related Content

Novartis Is Confident In Prexige’s Prospects Despite Arcoxia AC Debacle
Novartis Is Confident In Prexige’s Prospects Despite Arcoxia AC Debacle
Novartis Adds Reps In Face Of Big Pharma Cuts, Citing Pipeline, Portfolio
Novartis Adds Reps In Face Of Big Pharma Cuts, Citing Pipeline, Portfolio
Mobic May Gain Momentum After Bextra Withdrawal
Mobic May Gain Momentum After Bextra Withdrawal
FDA Discloses Safety Reviews Of COX-2s Arcoxia, Prexige and Parecoxib
Prexige TARGET Study: Not Quite A Bull’s-Eye For Novartis
Advertisement
UsernamePublicRestriction

Register

PS047758

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel